![](/PHGKB/images/hot_topic_banner.jpg)
Archive
Hot Topics of the Day are picked by experts to capture the latest information and publications on public health genomics and precision health for various diseases and health topics. Sources include published scientific literature, reviews, blogs and popular press articles.
The State of State Biomarker Testing Insurance Coverage Laws
(Posted: May 14, 2024 3PM)
Racial and ethnic disparities in genomic testing among lung cancer patients: a systematic review.
Clare Meernik et al. J Natl Cancer Inst 2024 2
(Posted: Feb 11, 2024 10AM)
Concurrent Circulating Tumor DNA and Tissue Genotyping-Ready for Prime Time?
Benjamin A Bleiberg et al. JAMA Netw Open 2024 1 (1) e2351679
(Posted: Jan 23, 2024 7AM)
Lung cancer in patients who have never smoked - an emerging disease.
Jaclyn LoPiccolo et al. Nat Rev Clin Oncol 2024 1
(Posted: Jan 11, 2024 7AM)
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
John V Heymach et al. N Engl J Med 2023 10 (18) 1672-1684
(Posted: Nov 02, 2023 9AM)
Emerging cancer risks in BRCA2 pathogenic germline variant carriers.
Patrick R Benusiglio et al. Eur J Hum Genet 2023 9
(Posted: Sep 28, 2023 11AM)
Assessing a Polygenic Risk Score for Lung Cancer Susceptibility in Non-Hispanic White and Black Populations.
Matthew R Trendowski et al. Cancer Epidemiol Biomarkers Prev 2023 8
(Posted: Aug 15, 2023 2PM)
Genetic Profiles Affect Smokers' Lung Cancer Risk
CN Martimez, Medscape, August 2023
(Posted: Aug 11, 2023 11AM)
The Inflammatory Profile Correlates with COVID-19 Severity and Mortality in Cancer Patients
CE Budin et al, JPM, August 7, 2023
(Posted: Aug 08, 2023 8PM)
Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment.
Michael P Douglas et al. J Natl Compr Canc Netw 2023 6 (6) 609-616.e4
(Posted: Jun 14, 2023 9AM)
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
M Tsuboi et al, NEJM, June 4, 2023
(Posted: Jun 05, 2023 8AM)
Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review.
Antonio Passaro et al. JAMA Oncol 2023 5
(Posted: May 12, 2023 6AM)
High-resolution circulating tumor DNA testing predicts survival in metastatic lung cancer clinical trials.
et al. Nat Med 2023 4
(Posted: Apr 15, 2023 8AM)
Molecular Marker Testing in Curable Non-Small Cell Lung Cancer-Practice Necessarily Precedes Data.
Charu Aggarwal et al. JAMA Oncol 2023 4
(Posted: Apr 15, 2023 8AM)
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA.
Christopher Abbosh et al. Nature 2023 4
(Posted: Apr 14, 2023 7AM)
Prognostic Mutational Signatures of NSCLC Patients treated with chemotherapy, immunotherapy and chemoimmunotherapy.
Margaret R Smith et al. NPJ precision oncology 2023 3 (1) 34
(Posted: Mar 28, 2023 6AM)
Top advances of the year: Precision oncology.
Aakash Desai et al. Cancer 2023 3
(Posted: Mar 23, 2023 6AM)
Towards the molecular era of discriminating multiple lung cancers
Z Wang, Ebiomedicine, March 21, 2023
(Posted: Mar 22, 2023 7AM)
A Comprehensive Analysis of Programmed Cell Death-Associated Genes for Tumor Microenvironment Evaluation Promotes Precise Immunotherapy in Patients with Lung Adenocarcinoma
Y Huang et al, J Per Med, March 7, 2023
(Posted: Mar 07, 2023 6PM)
Rare molecular subtypes of lung cancer.
Guilherme Harada et al. Nature reviews. Clinical oncology 2023 2
(Posted: Feb 23, 2023 9AM)
Integration of artificial intelligence in lung cancer: Rise of the machine.
Colton Ladbury et al. Cell reports. Medicine 2023 2 100933
(Posted: Feb 05, 2023 11AM)
Persistent mutation burden drives sustained anti-tumor immune responses.
Noushin Niknafs et al. Nature medicine 2023 1
(Posted: Jan 27, 2023 7AM)
Variation in Use of Lung Cancer Targeted Therapies Across State Medicaid Programs, 2020-2021.
Thomas J Roberts et al. JAMA network open 2023 1 (1) e2252562
(Posted: Jan 26, 2023 6AM)
Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-free DNA in Patients With Non-Small Cell Lung Cancer.
Lee Kirsty W C et al. JAMA oncology 2022 12
(Posted: Dec 31, 2022 6AM)
Leveraging Artificial Intelligence to Improve Accuracy of Lung Cancer Screening
NCI Blog, December 16, 2022
(Posted: Dec 19, 2022 10AM)
Extracellular matrix profiles determine risk and prognosis of the squamous cell carcinoma subtype of non-small cell lung carcinoma
AL Parker et al, Genome Medicine, November 21, 2022
(Posted: Nov 21, 2022 8AM)
Development of a Molecular Blood-Based Immune Signature Classifier as Biomarker for Risks Assessment in Lung Cancer Screening.
Fortunato Orazio et al. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2022 9 (11) 2020-2029
(Posted: Nov 13, 2022 6AM)
Preliminary Experience of Liquid Biopsy in Lung Cancer Compared to Conventional Assessment: Light and Shadows
M Montella et al, J Per Med, November 12, 2022
(Posted: Nov 13, 2022 6AM)
Circulating tumor DNA as a novel prognostic indicator
A Vivancos et al, Nature Medicine, November 10, 2022
(Posted: Nov 11, 2022 5PM)
Disparity in checkpoint inhibitor utilization among commercially insured adult patients with metastatic lung cancer.
Li Meng et al. Journal of the National Cancer Institute 2022 11
(Posted: Nov 11, 2022 6AM)
Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non-Small-Cell Lung Cancer.
Sadik Helen et al. JCO precision oncology 2022 10 e2200246
(Posted: Nov 01, 2022 2PM)
Molecular Profiling in Non-Squamous Non-Small Cell Lung Carcinoma: Towards a Switch to Next-Generation Sequencing Reflex Testing
N Pujol et al, J Per Med, October 8, 2022
(Posted: Oct 10, 2022 11AM)
Personalized Prescription of Chemotherapy Based on Assessment of mRNA Expression of BRCA1, RRM1, ERCC1, TOP1, TOP2α, TUBβ3, TYMS, and GSTP1 Genes in Tumors Compared to Standard Chemotherapy in the Treatment of Non-Small-Cell Lung Cancer
MM Tsyganov et al, J Per Medicine, October 4, 2022
(Posted: Oct 04, 2022 9AM)
Fibroblast subsets in non-small cell lung cancer: associations with survival, mutations, and immune features.
Pellinen Teijo et al. Journal of the National Cancer Institute 2022 9
(Posted: Sep 11, 2022 9AM)
Broad clinical manifestations of polygenic risk for coronary artery disease in the Women’s Health Initiative
SL Clarke et al, Comm Medicine, August 25, 2022
(Posted: Aug 26, 2022 8AM)
The oral microbiome and lung cancer risk: An analysis of 3 prospective cohort studies
E Vogtman et al, JNCI, August 5, 2022
(Posted: Aug 06, 2022 6AM)
Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer
J Byun et al, Nature Genetics, August 1, 2022
(Posted: Aug 01, 2022 11AM)
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
YY Elamin et al, Cell, July 11, 2022
(Posted: Jul 11, 2022 11AM)
When can we be confident of surgical cure with ctDNA?
Frankell Alexander et al. Nature reviews. Clinical oncology 2022 7
(Posted: Jul 10, 2022 2PM)
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.
Ricciuti Biagio et al. JAMA oncology 2022 6
(Posted: Jun 18, 2022 10AM)
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
AJ Cooper et al, Nature Rev Clin Oncology, May 2022
(Posted: May 14, 2022 11AM)
Longitudinal COVID-19 vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer
PC Mack et al, Cell, April 19 2022
(Posted: Apr 21, 2022 7AM)
A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy
T Rajakumar et al, NPJ Precision ONcology, March 31, 2022
(Posted: Apr 02, 2022 8AM)
Co-occurring genomic alterations and immunotherapy efficacy in NSCLC
F Zhang et al, NPJ Precision Oncology, January 18, 2022
(Posted: Jan 18, 2022 7AM)
A lepidic gene signature predicts patient prognosis and sensitivity to immunotherapy in lung adenocarcinoma
LT Nguyen et al, Genome Medicine, January 12, 2022
(Posted: Jan 12, 2022 8AM)
Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern.
R Varanpalanbil et al, MEDRXIV, January 4,2022
(Posted: Jan 05, 2022 8AM)
Overall survival for oncology drugs approved for genomic indications
A Haslam et al, EJC, January 2022
(Posted: Dec 23, 2021 10AM)
Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes
SY Liu et al, Nature Comms, November 8, 2021
(Posted: Nov 08, 2021 7AM)
Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor–Positive Non–Small Cell Lung Cancer
JAMA Network Open, November 5,2021
(Posted: Nov 06, 2021 9AM)
Estimating Recurrence Risk in Resected Early-Stage Epidermal Growth Factor Receptor–Positive Non–Small Cell Lung Cancer
C D'Avella et al, JAMA Network Open, November 5, 2021
(Posted: Nov 06, 2021 9AM)
Single-cell RNA sequencing for the identification of early-stage lung cancer biomarkers from circulating blood
J Kim et al, NPJ Genomic Medicine, October 15, 2021
(Posted: Oct 16, 2021 7AM)
Genomic and evolutionary classification of lung cancer in never smokers
T Zhang et al, Nature Genetics, September 6, 2021
(Posted: Sep 07, 2021 6AM)
Assessing Clinical Outcomes in a Data-Rich World—A Reality Check on Real-World Data
JC Wong et al, JAMA Internal Med, July 26, 2021
(Posted: Jul 27, 2021 7AM)
Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
Skoulidis Ferdinandos et al. The New England journal of medicine 2021 6 (25) 2371-2381
(Posted: Jun 24, 2021 6AM)
FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy
FDA, May 28, 2021
(Posted: May 30, 2021 10AM)
Machine Learning for Early Lung Cancer Identification Using Routine Clinical and Laboratory Data.
Gould Michael K et al. American journal of respiratory and critical care medicine 2021
(Posted: Apr 09, 2021 10AM)
Adherence to NCCN ALK testing guidelines for patients with advanced non-small cell lung cancer in US Community Medical Centers.
Bernicker Eric H et al. The oncologist 2021
(Posted: Apr 09, 2021 10AM)
Rare deleterious germline variants and risk of lung cancer
Y Liu et al, NPJ Genomic Medicine, February 19, 2021
(Posted: Feb 20, 2021 0PM)
A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma.
Jones Gregory D et al. JAMA surgery 2021 Feb (2) e205601
(Posted: Feb 11, 2021 7AM)
Germline Whole-Exome Sequencing Reveals the Potential Role of Hereditary Predisposition and Therapeutic Implications in SCLC
ASCO Post, February 4, 2021
(Posted: Feb 07, 2021 7AM)
Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair–targeted therapies
C Tlemsani et al, Sci Trans Med, January 27, 2021
(Posted: Jan 28, 2021 8AM)
A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma
GD Jones et al JAMA SUregery, December 23, 2020
(Posted: Dec 24, 2020 7AM)
Artificial intelligence is improving the detection of lung cancer- Machine learning systems for early detection could save lives.
E Svoboda, Nature Outlook, November 18, 2020
(Posted: Nov 23, 2020 8AM)
How liquid biopsies allow smarter lung-cancer treatment- Technologies that count tumour cells in the blood promise to improve survival times.
B Placket, Nature Outlook, November 18, 2020
(Posted: Nov 23, 2020 8AM)
First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer.
Shaw Alice T et al. The New England journal of medicine 2020 Nov (21) 2018-2029
(Posted: Nov 19, 2020 11AM)
What Are the Risk Factors for Lung Cancer?
CDC, November 2020
(Posted: Nov 18, 2020 10AM)
Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44
AL Cummings et al, Nature Cancer, November 26, 2020
(Posted: Nov 17, 2020 8AM)
Improving lung cancer risk stratification leveraging whole transcriptome RNA sequencing and machine learning across multiple cohorts
Y Choi et al, Genome Medicine, October 2020
(Posted: Oct 24, 2020 10AM)
Deep Learning Using Chest Radiographs to Identify High-Risk Smokers for Lung Cancer Screening Computed Tomography: Development and Validation of a Prediction Model.
Lu Michael T et al. Annals of internal medicine 2020 Sep
(Posted: Sep 03, 2020 7AM)
Association of Cerebrospinal Fluid Tumor DNA Genotyping With Survival Among Patients With Lung Adenocarcinoma and Central Nervous System Metastases
YS Li et al, JAMA Network Open, August 4, 2020
(Posted: Aug 05, 2020 8AM)
Smoking, alcohol consumption, and cancer: A mendelian randomisation study in UK Biobank and international genetic consortia participants.
Larsson Susanna C et al. PLoS medicine 2020 Jul (7) e1003178
(Posted: Jul 29, 2020 8AM)
The National Lung Matrix Trial of personalized therapy in lung cancer.
Middleton Gary et al. Nature 2020 Jul
(Posted: Jul 17, 2020 10AM)
An umbrella approach to test lung cancer therapies
A Drilon et al, Nature News, July 15, 2020
(Posted: Jul 17, 2020 10AM)
Lung Adenocarcinoma (LUAD) Discoveries from two NCI Proteomics Consortia
NCI, July 9, 2020
(Posted: Jul 10, 2020 6AM)
Liquid biopsy for early stage lung cancer moves ever closer
C Rolfo et al, Nat Rev Clin Oncol, May 26, 2020
(Posted: May 27, 2020 9AM)
Mendelian randomization applied to pharmaceutical use: the case of metformin and lung cancer.
Yarmolinsky James et al. International journal of epidemiology 2020 May
(Posted: May 10, 2020 7AM)
Evaluating the Use of Circulating MicroRNA Profiles for Lung Cancer Detection in Symptomatic Patients
T Fehlmann et al, JAMA Oncology, March 5, 2020
(Posted: Mar 06, 2020 8AM)
CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in stage I, II resectable non-small cell lung cancer: a retrospective multicohort study for outcome prediction
P Vaidya et al, Lancet Digital Health, February 13, 2020
(Posted: Feb 14, 2020 8AM)
Smoke signals in the DNA of normal lung cells
Nature News, January 30, 2020
(Posted: Jan 31, 2020 9AM)
Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non–Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants- A Phase 2 Randomized Clinical Trial
N Bi et al, JAMA Network Open, December 18, 2019
(Posted: Dec 19, 2019 9AM)
Evidence That Established Lung Cancer Mortality Disparities in American Indians Are Not Due to Lung Cancer Genetic Testing and Targeted Therapy Disparities.
Begnaud Abbie et al. Clinical lung cancer 2019 Oct
(Posted: Nov 26, 2019 9AM)
Study Suggests Repurposed Drugs Might Treat Aggressive Lung Cancer
NIH Director's Blog, November 19, 2019
(Posted: Nov 21, 2019 7AM)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Hellmann Matthew D et al. The New England journal of medicine 2019 Nov (21) 2020-2031
(Posted: Nov 21, 2019 7AM)
Appraising the causal relevance of DNA methylation for risk of lung cancer.
Battram Thomas et al. International journal of epidemiology 2019 Sep
(Posted: Sep 26, 2019 8AM)
Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non–Small Cell Lung Cancer
Y Chen et al, JAMA Network Open, September 20, 2019
(Posted: Sep 22, 2019 0PM)
Cancer Patients Have Limited Understanding of Genomic Test Results
Health Analytics, September 2019
(Posted: Sep 18, 2019 9AM)
Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor–Mutated Lung Adenocarcinoma
JAMA Oncology, September 5, 2019
(Posted: Sep 06, 2019 7AM)
Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer: A Review
KC Arbour et al, JAMA, August 27, 2019
(Posted: Aug 28, 2019 7AM)
Liquid biopsy-based single-cell metabolic phenotyping of lung cancer patients for informative diagnostics
Z Li et al, Nature Comms, August 26, 2019
(Posted: Aug 27, 2019 7AM)
Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc Marine et al. Frontiers in immunology 2019 1505
(Posted: Aug 01, 2019 8AM)
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non–Small Cell Lung Cancer
A Meta-analysis and Individual Patient–Level Analysis
Y Yu et al, JAMA Network Open, July 10, 2019
(Posted: Jul 11, 2019 8AM)
Prediction of the 1-Year Risk of Incident Lung Cancer: Prospective Study Using Electronic Health Records from the State of Maine.
Wang Xiaofang et al. Journal of medical Internet research 2019 May 21(5) e13260
(Posted: May 22, 2019 8AM)
End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography
D Ardila et al, Nature Medicine, May 20, 2019
(Posted: May 20, 2019 11AM)
A.I. Took a Test to Detect Lung Cancer. It Got an A- Artificial intelligence may help doctors make more accurate readings of CT scans used to screen for lung cancer.
D Grady, NY Times, May 20, 2019
(Posted: May 20, 2019 11AM)
Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.
Singal Gaurav et al. JAMA 2019 Apr (14) 1391-1399
(Posted: Apr 10, 2019 7AM)
Atezolizumab Approved for Initial Treatment of Metastatic Lung Cancer
NCI, January 2019
(Posted: Jan 29, 2019 7AM)
For Early-Stage Lung Cancer, Study Identifies Potential New Biomarker, Treatment Target
NCI, January 3, 2019
(Posted: Jan 07, 2019 0AM)
Race, Poverty, and Initial Implementation of Precision Medicine for Lung Cancer.
Kehl Kenneth L et al. Journal of the National Cancer Institute 2018 Dec
(Posted: Dec 30, 2018 9AM)
Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities.
Eapen Mathew Suji et al. Drugs 2018 Nov (16) 1717-1740
(Posted: Nov 21, 2018 0PM)
Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma.
Su Kang-Yi et al. PloS one 2018 13(11) e0207001
(Posted: Nov 19, 2018 10AM)
Disclaimer: Articles listed in Hot Topics of the Day are selected by Public Health Genomics Branch to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Content source: